FindTrial
Sign In

Aflibercept treat and extend for macular edema secondary to branch retinal vein occlusion

Aflibercept treat and extend for macular edema secondary to branch retinal vein occlusion - Aflibercept treat and extend for branch retinal vein occlusion

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027100
Enrollment
50
Registered
2017-04-24
Start date
2017-04-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

branch retinal vein occlusion

Interventions

aflibercept treat and extend aflibercept prn

Sponsors

Jikei daisan hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Naive BRVO 2.BCVA 0.1-1.0 3.Disease duration < 3 months 4.NPA< 5DD

Exclusion criteria

Exclusion criteria: 1.Past history of vitrectomy or glaucoma surgery 2.Cataract surgery within 3 months 3.patients with diabetic retinopathy or central vein occlusion 4.IOP poor control

Design outcomes

Primary

MeasureTime frame
Change in best corrected visual acuity at 12 months after intravitreal aflibercept—

Countries

Japan

Contacts

Public ContactTsutomu Sakai

Jikei daisan hospital Ophthalmology

tstmski@jikei.ac.jp0334801151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026